research use only
Cat.No.S2413
| Related Targets | PD-1/PD-L1 CXCR STING AhR CD markers Interleukins Anti-infection Antioxidant COX Histamine Receptor |
|---|---|
| Other Immunology & Inflammation related Inhibitors | Cl-amidine Bestatin (Ubenimex) Tempol Tranilast Sinomenine GI254023X (GI4023) CORM-3 Acacetin Germacrone Oxymatrine |
|
In vitro |
DMSO
: 16 mg/mL
(42.74 mM)
Ethanol : 2 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 374.34 | Formula | C16H22O10 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 27741-01-1 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | C1C=C(C2C1C(=COC2OC3C(C(C(C(O3)CO)O)O)O)C(=O)O)CO | ||
| In vivo |
Geniposidic acid shows a more remarkable inhibitory activity factor against implanted tumor growth when the doses of 500 mg/kg are given alone or combined with irradiation. Geniposidic acid improves the plaque area, intima/media thickness ratio, and intimal foam cells number in rabbits. Geniposidic acid (100 μg/mL) results in relieving ECs shedding and improving aortic morphology disorders in rabbits. Geniposidic acid (100 μg/mL) performs significant inhibition on smooth muscle cells proliferation in rabbits. Geniposidic acid results in obvious inhibition on SMC migration from the upper chamber. Geniposidic acid increases survival rate of rats with fulminant hepatic failure. Geniposidic acid attenuates the following effects: GalN/LPS increases serum aminotransferase activity, serum tumor necrosis factor-α level and hepatic lipid peroxidation and decreases hepatic glutathione content. Geniposidic acid augmentes increases in serum interleukin-6 level, heme oxygenase-1 and NF-E2-related factor 2 protein expression in rats with fulminant hepatic failure. Geniposidic acid decreases cleaved caspase-8 and caspase-3 protein expression and shows significantly fewer apoptotic cells in rats with fulminant hepatic failure. Geniposidic acid increases Bcl-xL protein expression and decreased Bax protein expression in rats with fulminant hepatic failure. Geniposidic acid treatment enhances phosphorylation of signal transducer and activator of transcription 3 in rats with fulminant hepatic failure.
|
References |
|
|---|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.